CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Low Dose Radiation TherapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2806 draw blood Wiki 0.71
drug332 Best Practice Wiki 0.41
drug1978 Questionnaire Wiki 0.15

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.08

There are 2 clinical trials

Clinical Trials


1 The RESCUE 1-19 Trial: Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19

This phase I/II trial studies low-dose radiation therapy as a focal anti-inflammatory treatment for patients with pneumonia or SARS associated with COVID-19 infection.

NCT04366791 Pneumonia Coronavirus Infection in 2019 (COVID-19) Severe Acute Respiratory Syndrome (SARS) Pneumonia Radiation: Low Dose Radiation Therapy
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: The rate will be reported, along with a two-sided 95% exact binomial confidence interval, using the Clopper-Pearson method. The observed extubation rate will be compared to the null rate of 20% using a two-sided binomial test. Statistical significance is assessed at the 0.05 level.

Measure: Rate of extubation (for intubated patients)

Time: Screening up to 28 days after radiation therapy

Secondary Outcomes

Description: Temperature in degrees (F)

Measure: Clinical outcome - Temperature

Time: Screening up to 28 days after radiation therapy

Description: Heart rate in beats per minutes

Measure: Clinical outcome - Heart Rate

Time: Screening up to 28 days after radiation therapy

Description: Systolic blood pressure in mm Hg

Measure: Clinical outcome - Systolic blood pressure

Time: Screening up to 28 days after radiation therapy

Description: Oxygen saturation in percentage

Measure: Clinical outcome - Oxygenation

Time: Screening up to 28 days after radiation therapy

Description: Respiratory rate in breaths per minute

Measure: Clinical outcome - Respirations

Time: Screening up to 28 days after radiation therapy

Description: FI02 in percentage

Measure: Clinical outcome - FiO2

Time: Screening up to 28 days after radiation therapy

Description: Positive end expiratory pressure (PEEP) in cm H20

Measure: Clinical outcome - PEEP

Time: Screening up to 28 days after radiation therapy

Description: Tidal volume in mL

Measure: Clinical outcome - Tidal volume

Time: Screening up to 28 days after radiation therapy

Description: Extubation/intubation events in percentage

Measure: Clinical outcome - Intubation/Extubation events

Time: Screening up to 28 days after radiation therapy

Description: Survival in percentage

Measure: Clinical outcome - Overall survival

Time: Screening up to 28 days after radiation therapy

Description: Serial chest x-rays categorized using published scale into ordinal ranks 1-5 for SARS.

Measure: Radiographic outcome - Chest xray

Time: Screening up to 28 days after radiation therapy

Description: CT scans with volume of consolidation measured in cubic centimeters.

Measure: Radiographic outcome - CT can

Time: Screening up to 28 days after radiation therapy

Description: White blood cell count in cell count x 10^3/mcL

Measure: Serologic outcome - WBC

Time: Screening up to 28 days after radiation therapy

Description: Hemoglobin in gm/dL

Measure: Serologic outcome - Hgb

Time: Screening up to 28 days after radiation therapy

Description: Procalcitonin in ng/mL

Measure: Serologic outcome - Procalcitonin

Time: Screening up to 28 days after radiation therapy

Description: Absolute neutrophil count in cell count x 10^3/mcL

Measure: Serologic outcome - ANC

Time: Screening up to 28 days after radiation therapy

Description: Creatine kinase in units/L

Measure: Serologic outcome - Creatine kinase

Time: Screening up to 28 days after radiation therapy

Description: Myoglobin in ng/mL

Measure: Serologic outcome - Myoglobin

Time: Screening up to 28 days after radiation therapy

Description: Albumin in gm/dL

Measure: Serologic outcome - Albumin

Time: Screening up to 28 days after radiation therapy

Description: Coagulation pathway time in seconds

Measure: Serologic outcome - PT/PTT

Time: Screening up to 28 days after radiation therapy

Description: D-Dimer in ng/mL

Measure: Serologic outcome - D-Dimer

Time: Screening up to 28 days after radiation therapy

Description: Gamma-glutamyl transferase in units/L

Measure: Serologic outcome - GGT

Time: Screening up to 28 days after radiation therapy

Description: Trygliciericdes in mg/dL

Measure: Serologic outcome -Triglycerides

Time: Screening up to 28 days after radiation therapy

Description: Ferritin in ng/mL

Measure: Serologic outcome -Ferritin

Time: Screening up to 28 days after radiation therapy

Description: Fibrinogen in mg/dL

Measure: Serologic outcome -Fibrinogen

Time: Screening up to 28 days after radiation therapy

Description: Immune marker flow cytometry (refractive index)

Measure: Serologic Immune markers flow cytometry

Time: Screening up to 28 days after radiation therapy

Description: Bilirubin in mg/dL

Measure: Serologic outcome -Bilirubin

Time: Screening up to 28 days after radiation therapy

Description: Lactate Dehydrogenase in units/L

Measure: Serologic outcome - LDH

Time: Screening up to 28 days after radiation therapy

Description: Creatinine in mg/dL

Measure: Serologic outcome - Creatinine

Time: Screening up to 28 days after radiation therapy

Description: Estimated Glomerular Filtration Rate in mL/min/m2

Measure: Serologic outcome - EGFR

Time: Screening up to 28 days after radiation therapy

Description: C-Reactive Protein in mg/L

Measure: Serologic outcome - CRP

Time: Screening up to 28 days after radiation therapy

Description: Alanine Aminotransferase in units/L

Measure: Serologic outcome - ALT

Time: Screening up to 28 days after radiation therapy

Description: Asparatate Aminotransferase in units/L

Measure: Serologic outcome - AST

Time: Screening up to 28 days after radiation therapy

Description: Troponin-I in ng/mL

Measure: Serologic outcome - Troponin-I

Time: Screening up to 28 days after radiation therapy

Description: B-Natriuretic Peptid in pg/mL

Measure: Serologic outcome - BNP

Time: Screening up to 28 days after radiation therapy

Description: pH (no unit)

Measure: Serologic outcome - Blood Gases pH

Time: Screening up to 28 days after radiation therapy

Description: pressure of O2 in mm Hg

Measure: Serologic outcome - Blood Gases pO2

Time: Screening up to 28 days after radiation therapy

Description: pressure of CO2 in mm Hg

Measure: Serologic outcome - Blood Gases pCO2

Time: Screening up to 28 days after radiation therapy

Description: Lactic Acid in mmol/L

Measure: Serologic outcome - Lactic Acid

Time: Screening up to 28 days after radiation therapy

Description: Interleukin-6 in pg/mL

Measure: Serologic outcome - IL-6

Time: Screening up to 28 days after radiation therapy

Description: Potassium in mmol/L

Measure: Serologic outcome - Potassium

Time: Screening up to 28 days after radiation therapy

2 Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19): A Randomized Phase III of Best Supportive Care +/- Whole Lung Low-Dose Radiation Therapy in Hospitalized Patients

This phase III trial compares low dose whole lung radiation therapy to best supportive care plus physicians choice in treating patients with COVID-19 infection. Low dose whole lung radiation therapy may work better than the current best supportive care and physician's choice in improving patients' clinical status, the radiographic appearance of their lungs, or their laboratory blood tests.

NCT04433949 Pneumonia Severe Acute Respiratory Syndrome Symptomatic COVID-19 Infection Laboratory-Confirmed Other: Best Practice Radiation: Low Dose Radiation Therapy
MeSH:Laboratory Infection Severe Acute Respiratory Syndrome Coronavirus Infections Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Will be measured by improvements on oxygenation need prior to intervention compared with after intervention and/or hospital discharge.

Measure: Time to clinical recovery

Time: Up to follow-up day 14 after study start

Secondary Outcomes

Description: The rates from both cohort will be reported.

Measure: Freedom from ICU admission

Time: Up to follow-up day 14 after study start; This may be extended up to 28 days after preplanned interim analysis.

Description: Temperature in degrees (F)

Measure: Temperature

Time: Up to follow-up day 14 after study start

Description: Heart rate in beats per minutes

Measure: Heart rate

Time: Up to follow-up day 14 after study start

Description: Systolic blood pressure in mm Hg

Measure: Systolic Blood pressure

Time: Up to follow-up day 14 after study start

Description: Oxygen saturation in percentage

Measure: Oxygen saturation

Time: Up to follow-up day 14 after study start

Description: Oxygen saturation in percentage

Measure: Supplemental oxygenation need

Time: Up to follow-up day 14 after study start

Description: Respiratory rate in breaths per minute.

Measure: Respiratory rate

Time: Up to follow-up day 14 after study start

Description: Pre and post intervention; Minimum of 3 (poor) to best (15)

Measure: Glasgow Comma Scale from minimum of 3 to maximum of 15.

Time: Up to follow-up day 14 after study start

Description: Easter Cooperative Oncology Group (ECOG) Performance Status Scale from 0-5; 0 being best; 5 being dead;

Measure: Performance status

Time: Up to follow-up day 14 after study start

Description: Survival in percentage

Measure: Survival

Time: Up to follow-up day 14 after study start; This may be extended to 28 days after preplanned interim analysis.

Description: Serial chest x-rays categorized using published scale into ordinal ranks 1-5 for SARS.

Measure: Serial chest x-rays severe acute respiratory syndrome (SARS) scoring

Time: Up to follow-up day 14 after study start;

Description: CT scans with volume of consolidation measured in cubic centimeters.

Measure: Changes on computed tomography (CT) scans pre and post RT

Time: Baseline up to follow-up day 14 after study start

Description: C-Reactive Protein in mg/L

Measure: CRP

Time: Up to follow-up day 14 after study start

Description: Will be summarized descriptively.

Measure: Serum chemistry + complete blood cell (CBC) with differential

Time: Up to follow-up day 14 after study start

Description: pH (no unit)

Measure: Blood gases pH(when available)

Time: Up to follow-up day 14 after study start

Description: Albumin in gm/dL

Measure: Albumin

Time: Up to follow-up day 14 after study start

Description: Procalcitonin in ng/mL

Measure: Procalcitonin

Time: Up to follow-up day 14 after study start

Description: Asparatate Aminotransferase in units/L

Measure: Aspartate aminotransferase (AST)

Time: Up to follow-up day 14 after study start

Description: Creatinine in mg/dL

Measure: Creatine kinase

Time: Up to follow-up day 14 after study start

Description: Coagulation pathway time in seconds

Measure: Prothrombin time (PT)/partial thromboplastin time (PTT)

Time: Up to follow-up day 14 after study start

Description: Troponin-I in ng/mL

Measure: Troponin

Time: Up to follow-up day 14 after study start

Description: Lactic Acid in mmol/L

Measure: Lactate

Time: Up to follow-up day 14 after study start

Description: B-Natriuretic Peptid in pg/mL

Measure: NT-pBNP (cardiac injury)

Time: Up to follow-up day 14 after study start

Description: Gamma-glutamyl transferase in units/L

Measure: Gamma-glutamyl transferase (GGT)

Time: Up to follow-up day 14 after study start

Description: Trygliciericdes in mg/dL

Measure: Triglycerides

Time: Up to follow-up day 14 after study start

Description: Fibrinogen in mg/dL

Measure: Fibrinogen

Time: Up to follow-up day 14 after study start

Description: Will be summarized descriptively.

Measure: Changes in CD8 T cells

Time: Up to follow-up day 14 after study start

Description: Will be summarized descriptively.

Measure: Changes in CD4 T cells

Time: Up to follow-up day 14 after study start

Description: Will be summarized descriptively.

Measure: Changes in serum antibodies against COVID-19 epitope

Time: Up to follow-up day 14 after study start

Description: Lactate Dehydrogenase in units/L

Measure: LDH

Time: Up to follow-up day 14 after study start

Description: D-Dimer in ng/mL

Measure: D-Dimer

Time: Up to follow-up day 14 after study start

Description: Interleukin-6 in pg/mL

Measure: IL-6

Time: Up to follow-up day 14 after study start

Description: Myoglobin in ng/mL

Measure: Myoglobin

Time: Up to follow-up day 14 after study start

Description: Potassium in mmol/L

Measure: Potassium

Time: Up to follow-up day 14 after study start

Description: Ferritin in ng/mL

Measure: Ferritin

Time: Up to follow-up day 14 after study start

Description: Alanine Aminotransferase in units/L

Measure: ALT

Time: Up to follow-up day 14 after study start


Related HPO nodes (Using clinical trials)